Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dolutegravir, a next-generation integrase strand transfer inhibitor, was recently approved by the United States Foodand Drug Administration to treat antiretroviral therapy-naive as well as treatment-experienced HIV-infected individuals, including those who have been treated with other integrase strand transfer inhibitors. Dolutegravir is the first stand-alone agent in its class, with a pharmacokinetic profile that allows once-daily administration without the requirement for pharmacologic boosting. It is metabolized primarily by UDP-glucuronosyltransferase 1-1 (UGT1A1) and is expected to have a limited propensity for drug-druginteractions. Furthermore, dolutegravir retains significant virologic activity against raltegravir- or elvitegravir-associated HIV-1 resistance mutations.

Original languageEnglish (US)
Pages (from-to)7-14
Number of pages8
JournalDrugs of Today
Volume50
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

HIV Integrase Inhibitors
HIV Infections
Integrases
Glucuronosyltransferase
Pharmaceutical Preparations
HIV-1
Pharmacokinetics
HIV
Mutation
dolutegravir
Therapeutics

Keywords

  • Anti-HIV agents
  • Antiretroviral-naive
  • Dolutegravir
  • GSK-1349572
  • HIV integrase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection. / Temesgen, Zelalem; Talwani, R.; Rizza, Stacey.

In: Drugs of Today, Vol. 50, No. 1, 01.2014, p. 7-14.

Research output: Contribution to journalArticle

@article{0c913feaea894e9c8936386b7f5efa65,
title = "Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection",
abstract = "Dolutegravir, a next-generation integrase strand transfer inhibitor, was recently approved by the United States Foodand Drug Administration to treat antiretroviral therapy-naive as well as treatment-experienced HIV-infected individuals, including those who have been treated with other integrase strand transfer inhibitors. Dolutegravir is the first stand-alone agent in its class, with a pharmacokinetic profile that allows once-daily administration without the requirement for pharmacologic boosting. It is metabolized primarily by UDP-glucuronosyltransferase 1-1 (UGT1A1) and is expected to have a limited propensity for drug-druginteractions. Furthermore, dolutegravir retains significant virologic activity against raltegravir- or elvitegravir-associated HIV-1 resistance mutations.",
keywords = "Anti-HIV agents, Antiretroviral-naive, Dolutegravir, GSK-1349572, HIV integrase inhibitors",
author = "Zelalem Temesgen and R. Talwani and Stacey Rizza",
year = "2014",
month = "1",
doi = "10.1358/dot.2014.50.1.2097790",
language = "English (US)",
volume = "50",
pages = "7--14",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "1",

}

TY - JOUR

T1 - Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection

AU - Temesgen, Zelalem

AU - Talwani, R.

AU - Rizza, Stacey

PY - 2014/1

Y1 - 2014/1

N2 - Dolutegravir, a next-generation integrase strand transfer inhibitor, was recently approved by the United States Foodand Drug Administration to treat antiretroviral therapy-naive as well as treatment-experienced HIV-infected individuals, including those who have been treated with other integrase strand transfer inhibitors. Dolutegravir is the first stand-alone agent in its class, with a pharmacokinetic profile that allows once-daily administration without the requirement for pharmacologic boosting. It is metabolized primarily by UDP-glucuronosyltransferase 1-1 (UGT1A1) and is expected to have a limited propensity for drug-druginteractions. Furthermore, dolutegravir retains significant virologic activity against raltegravir- or elvitegravir-associated HIV-1 resistance mutations.

AB - Dolutegravir, a next-generation integrase strand transfer inhibitor, was recently approved by the United States Foodand Drug Administration to treat antiretroviral therapy-naive as well as treatment-experienced HIV-infected individuals, including those who have been treated with other integrase strand transfer inhibitors. Dolutegravir is the first stand-alone agent in its class, with a pharmacokinetic profile that allows once-daily administration without the requirement for pharmacologic boosting. It is metabolized primarily by UDP-glucuronosyltransferase 1-1 (UGT1A1) and is expected to have a limited propensity for drug-druginteractions. Furthermore, dolutegravir retains significant virologic activity against raltegravir- or elvitegravir-associated HIV-1 resistance mutations.

KW - Anti-HIV agents

KW - Antiretroviral-naive

KW - Dolutegravir

KW - GSK-1349572

KW - HIV integrase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84893656036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893656036&partnerID=8YFLogxK

U2 - 10.1358/dot.2014.50.1.2097790

DO - 10.1358/dot.2014.50.1.2097790

M3 - Article

VL - 50

SP - 7

EP - 14

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 1

ER -